BioCentury | May 2, 2011
Finance

Oxford bulks up

...disease play Anacor Pharmaceuticals Inc. (NASDAQ:ANAC); a $20 million senior credit facility for ophthalmic company NeoVista Inc....
BioCentury | Mar 21, 2011
Financial News

NeoVista financial update

...secured $20 million in a senior credit facility from Oxford Finance Corp. and GE Capital. NeoVista Inc....
BioCentury | Mar 18, 2011
Financial News

NeoVista secures $20M credit facility

...Calif.) secured $20 million in a credit facility from Oxford Finance Corp. and GE Capital. NeoVista's...
BioCentury | Feb 21, 2011
Financial News

NeoVista completes venture financing

NeoVista Inc. , Fremont, Calif. Business: Ophthalmic Date completed: 2/10/11 Type: Venture financing Raised: $33.8 million Investors: Versant Ventures; Accuitive Medical Ventures; Carlyle Venture Partners; SV Life Sciences; MPM Capital WIR Staff...
BioCentury | Feb 19, 2011
Financial News

NeoVista raises $33.8 million

...Ophthalmic company NeoVista Inc. (Fremont, Calif.) raised $33.8 million in a series E round from Versant Ventures...
...from Versant Ventures; Accuitive Medical Ventures; Carlyle Venture Partners; SV Life Sciences; and MPM Capital. NeoVista's...
BioCentury | Jun 18, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

...photodynamic therapy, Photrex rostaporfin, is in Phase III testing to treat CNV associated with AMD. NeoVista Inc.'s...
BioCentury | Mar 2, 2009
Product Development

Changing the game in AMD

...on both fronts. While most biotechs in the space are focused on me-better VEGF treatments, NeoVista Inc....
...per dose and most patients need injections every 4-6 weeks for at least two years. NeoVista...
...non-inferior to Lucentis, then Epi-Rad90's cost benefits over Lucentis alone might become irrelevant. Radiation therapy NeoVista...
Items per page:
1 - 7 of 7
BioCentury | May 2, 2011
Finance

Oxford bulks up

...disease play Anacor Pharmaceuticals Inc. (NASDAQ:ANAC); a $20 million senior credit facility for ophthalmic company NeoVista Inc....
BioCentury | Mar 21, 2011
Financial News

NeoVista financial update

...secured $20 million in a senior credit facility from Oxford Finance Corp. and GE Capital. NeoVista Inc....
BioCentury | Mar 18, 2011
Financial News

NeoVista secures $20M credit facility

...Calif.) secured $20 million in a credit facility from Oxford Finance Corp. and GE Capital. NeoVista's...
BioCentury | Feb 21, 2011
Financial News

NeoVista completes venture financing

NeoVista Inc. , Fremont, Calif. Business: Ophthalmic Date completed: 2/10/11 Type: Venture financing Raised: $33.8 million Investors: Versant Ventures; Accuitive Medical Ventures; Carlyle Venture Partners; SV Life Sciences; MPM Capital WIR Staff...
BioCentury | Feb 19, 2011
Financial News

NeoVista raises $33.8 million

...Ophthalmic company NeoVista Inc. (Fremont, Calif.) raised $33.8 million in a series E round from Versant Ventures...
...from Versant Ventures; Accuitive Medical Ventures; Carlyle Venture Partners; SV Life Sciences; and MPM Capital. NeoVista's...
BioCentury | Jun 18, 2009
Distillery Therapeutics

Indication: Ophthalmic disease

...photodynamic therapy, Photrex rostaporfin, is in Phase III testing to treat CNV associated with AMD. NeoVista Inc.'s...
BioCentury | Mar 2, 2009
Product Development

Changing the game in AMD

...on both fronts. While most biotechs in the space are focused on me-better VEGF treatments, NeoVista Inc....
...per dose and most patients need injections every 4-6 weeks for at least two years. NeoVista...
...non-inferior to Lucentis, then Epi-Rad90's cost benefits over Lucentis alone might become irrelevant. Radiation therapy NeoVista...
Items per page:
1 - 7 of 7